Lavender Swirl Background


Insilico Medicine, Inc.

Data Science holds the promise for faster drug discovery, development and testing. Insilico will deliver on that promise.

Insilico Medicine develops artificial intelligence systems that utilize deep generative models, reinforcement learning (RL), transformers, and other modern machine learning techniques for the generation of new molecular structures with specific properties.

Insilico will lead by relentlessly innovating, publishing proofs of concept and delivering AI software that deploys the latest technology. A key concept to Insilico’s approach is ruthless internal competition, where different models compete against each other to rapidly prove which is superior and offers greater results. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trials outcomes.

Insilico’s capabilities can be leveraged by Juvenescence to speed hit-to-lead discovery.

For more information, please visit

In the News


Longevity Companies to Watch in 2021

Juvenescence and its partners – the Buck Institute for Research on Aging, Insilico Medicine, and LyGenesis – have been identified as leaders who are driving important scientific advances in the longevity field.

January 4, 2021

Read More
Insilico Medicine

Insilico Enters Into Research Collaboration with Pfizer Inc.

Insilico Medicine, a Juvenescence partner, enters into research collaboration with Pfizer Inc. to utilize Insilico’s machine learning technology to identify evidence for potential therapeutic targets implicated in a variety of diseases.

January 14, 2020

Read More
Insilico Medicine

Nature Biotech: ‘Deep learning enables rapid identification of potent DDR1 kinase inhibitors’

Insilico Medicine, a Juvenescence partner, recently highlighted their ability to use deep learning for de novo small-molecule design in Nature Biotech.

September 20, 2019

Read More
Contact Us
We are here to help answer any questions you might have.